Resources from the same session
Immune-Check Points Inhibitors (ICI) in non-oncogenic addicted mNSCLC
Presenter: Marina Garassino
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast
EGFR mutant mNSCLC: Single agent or in combination?
Presenter: Fabrice Barlesi
Session: ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Resources:
Slides
Webcast